<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113864</url>
  </required_header>
  <id_info>
    <org_study_id>16-004</org_study_id>
    <nct_id>NCT03113864</nct_id>
  </id_info>
  <brief_title>Effects of Lutein on Visual Function</brief_title>
  <official_title>Beneficial Effects of Lutein on Visual Function in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kemin Foods LC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kemin Foods LC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo-controlled intervention trial on the ocular benefits and
      inflammatory markers improvements of taking FloraGLO Lutein for 9 months. The population of
      interest is middle-aged men and women who have low levels of carotenoids in their eyes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants will be given a brief explanation of the study and asked to sign an informed
      consent form. During the screening visit, pre-study parameters will be measured in order to
      assess the subjects' eligibility to participate.

      These include:

        1. Medical History

        2. Vital signs, Height and weight and BMI calculation

        3. Visual Parameters

        4. Blood draw for clinical chemistry and hematological safety

      Intervention Period:

      At baseline visual parameters and a serum sample for analysis of inflammatory markers will be
      taken. Supplements will be dispensed. Study visits will then be conducted every 3 months. At
      these visits, subjects will have visual parameters, adverse events, study diary, vitals, a
      questionnaire evaluating health/diet/exercise/alcohol, product distribution and compliance
      checked. A final serum/plasma sample will be taken at the final visit for re-assessment of
      safety parameters and inflammatory markers.

      Compliance check:

      The number of tablets dispensed at baseline and returned, as well as all intake information
      from a subject diary. Per protocol population is defined apriori as &gt;80%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Parallel Intervention Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All parties involved in the study are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary outcome: Cone Sensitivity Recovery</measure>
    <time_frame>9 months</time_frame>
    <description>Visual Parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary outcome: Chromatic Contrast Sensitivity</measure>
    <time_frame>9 months</time_frame>
    <description>Visual Parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dark Adaption</measure>
    <time_frame>9 months</time_frame>
    <description>Visual Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular Pigment Optical Density</measure>
    <time_frame>9 months</time_frame>
    <description>Visual Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>9 months</time_frame>
    <description>Visual Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement Factor D, C5a, and MAC</measure>
    <time_frame>9 months</time_frame>
    <description>Inflammatory Marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Carotenoid Levels</measure>
    <time_frame>9 months</time_frame>
    <description>Blood Marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <condition>Nutrition Poor</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will be identical looking to treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lutein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg of FloraGLO Lutein</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily supplementation for 9 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein</intervention_name>
    <description>Daily Supplementation for 9 months</description>
    <arm_group_label>Lutein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age 40-60 years

          -  Corrected Visual Acuity of 20/20 to 20/25

          -  MPOD 0.05- 0.30 OD units

          -  Must be able to give written informed consent in English

          -  BMI &lt; or = 30 kg/m2

          -  Subject is willing to maintain a habitual diet and physical activity patterns
             throughout the study period

        Exclusion Criteria:

          -  Use of carotenoid, fish oil, or n-3 fatty acid supplements (within 2 months of study
             start)

          -  Ocular pathologies

          -  History of active small bowel disease or resection

          -  Uncontrolled hypertension

          -  Diabetes mellitus

          -  Pancreatic disease

          -  Pregnancy (or planning to become pregnant) or lactation

          -  Diseases that interfere with fat absorption

          -  Medication or supplements that contain a significant level of carotenoids

          -  Medications that interfere with fat absorption

          -  Use of drugs suspected of interfering with metabolism of blood clotting

          -  Chronic alcohol intake

          -  Stroke, head injury with loss of consciousness or seizures

          -  Severe Amblyopia resulting in visual acuity worse than 0.4 MAR

          -  Subject is a heavy smoker (&gt; 1 pack/day)

          -  A regular consumer of lutein rich foods or lutein supplements

          -  A regular consumer of foods high in DHA intake or DHA supplements

          -  Subject has donated more than 300 mL of blood during the last three months prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelli A Herrlinger</last_name>
    <phone>5155595595</phone>
    <email>kelli.herrlinger@kemin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonas Wittwer</last_name>
    <phone>+41 61 815 8228</phone>
    <email>jonas.wittwer@dsm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Manchester</name>
      <address>
        <city>Manchester</city>
        <state>United Kindgom</state>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Murray, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vision</keyword>
  <keyword>Eye Health</keyword>
  <keyword>Lutein</keyword>
  <keyword>Carotenoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

